[ad_1]
The Ministry of Health draws attention to patients taking drugs containing the active ingredient valsartan. Some of the patients bought drugs that are currently being taken off the market and the next time they will go to a pharmacy to offer a drug from another manufacturer with the same active ingredient.
According to Christina Garuolienė, Deputy Minister of Health in all Member States. the withdrawal of the low-valsartan active substance, which began after Spain initiated an emergency withdrawal procedure and shared this information with other Member States and the European Medicines Agency in accordance with the established procedure. Based on this information, the National Agency for Drug Control (IERC) also initiated a procedure for removal of defective drugs from the Lithuanian pharmaceutical supply chain, including pharmacies (information published on the IWT website). , a very important role for pharmacies. In cases where the patient introduces and wishes to return a defective product containing valsartan, the pharmacy must accept it as a pharmaceutical waste, including blister packs.
To prevent the patient from being interrupted or inconvenienced by the purchase of another quality product The prescription of a no prescription prescription for a recidivist patient for 30 days may be given to the patient.
The pharmacy, substituting the poor quality product for a qualitatively equivalent product, must take into account the fact that it is the manufacturer of poor quality drugs that is responsible. gap "We hope that joint efforts will not harm the supply of high-quality drugs with valsartan and that pharmacies will take all necessary measures," said Deputy Minister Kristina Garuolienė.
We also recommend that residents who use drugs containing valsartan consult a physician to badess the need for this drug and other therapeutic alternatives.
Currently, the European Medicines Agency, with the participation of the Directorate for the Quality of Medicines Care and National Drug Agencies of EU Member States are conducting a review and evaluation more broad drugs sarartan group
[ad_2]
Source link
